Microparticle Products for the Eye: Preformulation, Formulation, and Manufacturing Considerations-Reference-Cited by-同舟云学术

Microparticle Products for the Eye: Preformulation, Formulation, and Manufacturing Considerations

Published:2021 Issue: Volume: Page:381-407
ISSN:2210-7371
Container-title:Ophthalmic Product Development
language:
Short-container-title:

Author:

Andrés-Guerrero Vanessa,Molina-Martínez Irene T.,Bravo-Osuna Irene,Herrero-Vanrell Rocío

Publisher

Springer International Publishing

Link

https://link.springer.com/content/pdf/10.1007/978-3-030-76367-1_14

Reference47 articles.

1. Addo RT, Siddig A, Siwale R, Patel NJ, Akande J, Uddin AN, D’Souza MJ. Formulation, characterization and testing of tetracaine hydrochloride-loaded albumin-chitosan microparticles for ocular drug delivery. J Microencapsul. 2010;27:95–104. https://doi.org/10.3109/02652040903010638.

2. Amrite AC, Ayalasomayajula SP, Cheruvu NP, Kompella UB. Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage. Invest Ophthalmol Vis Sci. 2006;47:1149–60. https://doi.org/10.1167/iovs.05-0531.

3. Amrite AC, Edelhauser HF, Singh SR, Kompella UB. Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration. Mol Vis. 2008;14:150–60. pii:v14/a20.

4. Arranz-Romera A, et al. Simultaneous co-delivery of neuroprotective drugs from multi-loaded PLGA microspheres for the treatment of glaucoma. J Control Release. 2019a;297:26–38. https://doi.org/10.1016/j.jconrel.2019.01.012.

5. Arranz-Romera A, Esteban-Pérez S, Garcia-Herranz D, Aragón-Navas A, Bravo-Osuna I, Herrero-Vanrell R. Combination therapy and co-delivery strategies to optimize treatment of posterior segment neurodegenerative diseases. Drug Discov Today. 2019b; https://doi.org/10.1016/j.drudis.2019.03.022.